Ivermectin and Mebendazole in Lymphoma and Leukemia: 29 Case Reports (2026)
Contents:
- Introduction
- Lymphoma Case Series (20 case reports)
- Leukemia Case Series (9 case reports)
- Discussion
- Conclusion
Introduction
Drug repurposing sits at the intersection of curiosity and caution. Ivermectin and mebendazole — long-used antiparasitic medications — have accumulated a growing body of laboratory evidence suggesting anticancer activity across multiple pathways. Meanwhile, a series of 29 reported cases involving lymphoma and leukemia patients describe tumor regression, remission, or hematologic normalization after incorporating these agents into their regimens.
The central question is not whether these reports “prove” efficacy. The more relevant question is whether they represent noise, coincidence, or early translational signals that warrant structured investigation..png)
Lymphoma Success Stories (20 cases)
Case 20 (2026): 73 year old Texas man with Stage 4 Marginal Zone Lymphoma* (MZL)
*Marginal zone lymphoma (MZL) refers to a group of rare, slow-growing non-Hodgkin lymphomas.
Dr William Makis posted on X.com in February 2026:
IVERMECTIN and FENBENDAZOLE - 73 year old Texas man with Stage 4 NHL Marginal Zone Lymphoma reports after 6 months: Cancer Free!
STORY:
73 year old Texas man with Stage 4 NHL Marginal Zone Lymphoma
In July 2025 he started:
- Ivermectin 48mg/day
- Fenbendazole 150mg/day
- Oncologist: Bendamustine and Rituximab
Case 19 (2026): 59 year old Victoria, AUSTRALIA man with Stage 3 Blastoid Mantle Cell Lymphoma
IVERMECTIN and FENBENDAZOLE Testimonial - 59 year old Victoria, AUSTRALIA man with Stage 3 Blastoid Mantle Cell Lymphoma was told to "say his goodbyes". He is doing great after 4 months!
Dr William Makis posted on X.com in February 2026:
IVERMECTIN and FENBENDAZOLE Testimonial - 59 year old Victoria, AUSTRALIA man with Stage 3 Blastoid Mantle Cell Lymphoma was told to "say his goodbyes". He is doing great after 4 months!
I have shocked another Australia Oncologist!
He told this 59yo cancer patient to "say his goodbyes".
Now he's doing great!
STORY:
59 year old Victoria, AUSTRALIA man with Stage 3 Blastoid Mantle Cell Lymphoma was told to “say his goodbyes”
In September 2025 he started:
Ivermectin 1.5mg/kg/day
Fenbendazole 1500mg/day
Results after 4 months:
“My Oncologist is happy with my bloods and my health”
“I would be having PET scans every 3 months but have had no symptoms to warrant one”
"Considering my cancer has been back 6 times over the last 6 years I am optimistic but still treat every day I live like a million dollars...once again I thank you"
Blastoid Mantle Cell Lymphoma is rare, highly aggressive with a poor response to conventional treatments and poor prognosis.
Case 18 (2026): 36 year old man in South France with Stage 4 Hodgkin Lymphoma
Dr William Makis posted on X.com in February 2026:
IVERMECTIN, FENBENDAZOLE and MEBENDAZOLE Testimonial - 36 year old man in South France with Stage 4 Hodgkin Lymphoma reports after 1 month
Cancer Patients in South of France benefiting!
STORY:
36 year old man in France with Stage 4 Hodgkin Lymphoma
In December 2025 he started (Makis Triple Therapy):
- Ivermectin 1.5mg/kg/day
- Fenbendazole 1500mg/day
- Mebendazole 1500mg/day
KEY POINT:
“Your protocol has already helped since I did not get any side effects from last (chemo) treatment done January 5th”.
Case 17 (2026): 40 year old Canadian man with DLBCL Lymphoma (Diffuse Large B-Cell Lymphoma) 9cm and 4cm masses in the right supraspinatus muscle
Dr William Makis posted on X.com in January 2026:
IVERMECTIN and FENBENDAZOLE Testimonial - 40 year old Canadian man with DLBCL Lymphoma 9cm and 4cm masses in the right supraspinatus muscle reports after 8 months - Cancer Free!
Lymphomas can be incredibly responsive!
STORY:
40 year old Canadian man with DLBCL Lymphoma 9cm and 4cm masses in the right supraspinatus muscle.
In May 2025 he started:
- Ivermectin 1mg/kg/day
- Fenbendazole 1500mg/day
- CBD Oil 100mg/day
Results after 3 cycles of Chemo (with Ivermectin Protocol): CANCER FREE
"My Oncologist stated after the 3rd round the cancer had disappeared".
"6 rounds R-CHOP - complete metabolic response. Cancer has disappeared".
"No side effects during treatment".
KEY POINT:
Soursop shows up in a lot of my success stories, even when I didn’t suggest it. That’s one of the reasons I started including it in my protocols regularly.
Soursop. Graviola. Add it to your diet. Don't be without it.
Case 16 (2026): 60 year old Massachusetts man with Stage 4 DLBCL (Diffuse Large B-Cell Lymphoma) metastatic to bones
We sometimes see incredible responses and in a short period of time!
Dr William Makis posted on X.com in January 2026:
IVERMECTIN, FENBENDAZOLE and IP6 Testimonial - 60 year old Massachusetts man with Stage 4 DLBCL LYMPHOMA metastatic to bones achieves remission in less than 2 months!
IVERMECTIN, FENBENDAZOLE and IP6 Testimonial - 60 year old Massachusetts man with Stage 4 DLBCL LYMPHOMA metastatic to bones achieves remission in less than 2 months!
We sometimes see incredible responses and in a short period of time!
60 year old Massachusetts man with Stage 4 DLBCL LYMPHOMA metastatic to bones.
In October he started taking IP6
In November, he started:
- Ivermectin 1mg/kg/day
- Fenbendazole 1776mg/day
By Dec.29, he was in “Complete Remission”.
KEY POINTS:
This is an incredible treatment response in such a short period of time - one month on the full protocol to complete remission, and some of the lymphoma tumors were quite large, the largest was 6cm!
We often see in preclinical studies that Ivermectin and Fenbendazole can dramatically improve the cancer cell killing efficacy of chemotherapy. This is a perfect example of that.
Case 15 (2025): 70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones
Stage 4 Cancer to remission, success story after success story.
Dr William Makis posted on X/Twitter in December 2025:
IVERMECTIN, FENBENDAZOLE, CBD Oil Testimonial - 70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones reports after 6 months - Remission!
IVERMECTIN, FENBENDAZOLE, CBD Oil Testimonial - 70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones reports after 6 months - Remission!
Stage 4 Cancer to remission, success story after success story.
STORY:
70 year old Oklahoma man with Stage 4 Follicular Lymphoma metastatic to bones
In early April 2025 he started:
Ivermectin: 1mg/kg/day Fenbendazole 1000mg/day CBD Oil 100mg/day
Oncologist: 6 rounds of RCHOP starting late May
Results: By July 22, 2025 his PET scan was clean!!
The images shown are of his May 22, 2025 (extensive metastases) and July 22, 2025 (clean) PET scans.
At this point he had been on IVM/FBZ 3-4 months.
Remission was confirmed again on a Sep.30, 2025 PET Scan.
KEY POINTS:
I now have Lymphoma success stories with complete remissions (confirmed by PET scans) of the following combinations:
Ivermectin + Fenbendazole + RCHOP Ivermectin + Mebendazole + RCHOP
Which is better? Literature seems to lean towards Mebendazole but I don’t have a definitive answer.
Both seem to work. That's wonderful news for cancer patients who sometimes have trouble getting one or the other (Fenbendazole or Mebendazole). From Stage 4 Cancer to remission is much more likely if you incorporate repurposed drugs.
Case 14 (2025): 65 year old Canadian Man with T-cell Anaplastic Lymphoma of the tonsils
IVERMECTIN and FENBENDAZOLE Testimonial - 65 year old Canadian Man with T-cell Anaplastic Lymphoma of the tonsils reports after 3 months.
On my way back home from El Salvador...what better time to post a testimonial?
STORY:
65 year old Canadian Man with T-cell Anaplastic Lymphoma of the tonsils
In early July 2025 he started:
Ivermectin 1mg/kg/day
Fenbendazole 1000mg/day
Chemotherapy
Results:
After the end of his 3rd chemotherapy (the CT Report here), his lymphoma sites had resolved. Ivermectin and Fenbendazole are chemosensitizers that enhance cancer cell killing by chemotherapy and we see very dramatic responses in many Lymphoma cases.
FENBENDAZOLE Testimonial - Wife of UK Architect shares an incredible B-cell Non-Hodgkin Lymphoma success story!
I've helped over 7000 cancer patients directly and countless more "indirectly".
Here is one of those heartwarming success stories.
"I was diagnosed with Lymphoma B-Cell Non-Hodgkin's high grade"
"the day I had my first chemotherapy in April he (my husband) showed me your interview with Dr.Campbell talking about the success of Fenbendazole"
"I had nothing to lose, so we ordered some online and four days later I started taking it"
Now, there is no Ivermectin in this story, so this one is really interesting...
"I started taking 222mg per day and soon increased the dose to 444mg after reading the comments below your podcast.
"I had a PET scan in June, and my haematologist was speechless. She had never seen this before, after one chemotherapy session, I had no more Lymphoma"
"my PET scan last week again showed I had no more Lymphoma"
"This time she asked if she could write up my case and said if she prescribed Fenbendazole she would be struck off"
Source: https://x.com/MakisMedicine/status/1985278795704844757 (November 2025)
Case 12 (2025): 46 year old Canadian man with Stage II Hodgkin Lymphoma
Source: https://x.com/MakisMD/status/1937984358432051382 (June 2025)
Ivermectin and Fenbendazole Testimonial - 46 yo Canadian man with Stage II Hodgkin Lymphoma (9x7x11cm mediastinal mass) goes into remission after 3 months with Ivermectin, Fenbendazole and Radiation!
An incredible story of lymphoma - from a massive 11cm mediastinal tumor to "Cancer Free".
46 year old Canadian man with Stage II Hodgkin Lymphoma (9x7x11cm mediastinal mass)
From Dec.2024 to March 2025, for 3 months, he took:
- Ivermectin 1mg/kg/day (increasing to 2mg/kg/day)
- Fenbendazole 1332mg/day
- CBD Oil 100mg/day
- Melatonin 300mg/day
Case 11 (2020): 83-year-old male with Diffuse Large B-Cell Lymphoma (DLBCL)
He started to take fenbendazole 1g daily based on self-research (used to take between 1-6 tabs daily based on his symptoms). After 6 months, he cut down fenbendazole to 1-3 tabs daily due to peripheral neuropathy. He presented to his primary care physician who obtained a repeated CT scan which revealed smaller mediastinal lymph nodes. After 2 months, he decided to follow with oncology, so he had repeated PET/CT scan which revealed improved lymphadenopathy from prior scans.
In the next 3 months, he continued to taper down fenbendazole and reached 3 pills weekly. A repeated PET/CT scan revealed interval improvement in his disease with no new lesion seen.
Source: Annals of Hematology & Oncology 2020
Mike Ridgway of Tennessee treated his early lymphoma with two shoeboxes of medications from India. Within eleven months, his three PET scans went from ominous to better to normal.
A retired software programmer, Ridgway took long-established, off-patent drugs that are surely not on a typical oncologist’s radar: ivermectin, fenbendazole (a veterinary drug), and colchicine. They cost $400 for six months of treatment. Standard pharmaceuticals for early lymphoma, by contrast, cost an average $12,396 a year in the United States.
Ridgway, who is sixty-five years old, represents a small share of cancer patients who choose alternative care in part because they mistrust profit-driven oncology and dislike the chemo drawbacks. The drugs they take—under the supervision of a physician and sometimes with traditional therapies—are supported by considerable laboratory and animal studies and some human research.
For cases in which the outcomes are known, he prescribed his ivermectin-fenbendazole cocktail to sixteen patients, who almost all had been given one to four weeks to live. Thirteen survived from six to ten months before dying, he said. One near-death pancreatic patient, who had exhausted the gamut of chemotherapy, lasted more than a year.
“It’s difficult to reverse the (chemotherapy) damage,” DeMello said, who has six other cases in various treatment stages.
In two of his first sixteen cases, however, patients bypassed traditional care and went first to DeMello. Rohini Hughes, a fity-three-year-old advanced colon cancer patient, is alive though suffering, twenty months after her remaining time was measured in days. Mike Ridgway, whose cancer was caught early, was given a clean bill of health nearly a year after the disease emerged.
“I cannot overstate how blessed my wife and I feel,” Ridgway said.
Ridgway became friends with DeMello through Facebook, where they shared like-minded views of the flaws of official pandemic policies.
Ridgway’s first inkling that he was facing a serious health problem was in February 2024 after suffering abdominal pain and enlarged lymph nodes. “This PET scan will find cancer anywhere in your body,” the technician told a startled Ridgway.
Indeed, the scan showed “two nodes in the left upper abdominal mesentery that are markedly hypermetabolic, and lymphoma is a primary consideration.”
An oncologist ordered a biopsy, telling Ridgway unequivocally, “The tissue is the issue.”
He turned to DeMello, who “was very, very emphatic against it,” Ridgway said.
“I am convinced that there is no useful role of biopsy (and risk of spreading cancer) especially when a non-invasive test like PET scan can confirm the presence of malignancy,” DeMello explained. “Two huge lymphomas” on Ridgway’s scan were diagnostic for him.
“Unless he had a major infection, with symptoms of fever, high WBC counts, high neutrophil counts,” he said, “the only diagnosis for such huge tumors in the abdomen is malignancy’.”
After that, Ridgway opted to follow the advice of a doctor he respected half a world away.
“It’s nothing short of a miracle that the two of us were in communication when I received my diagnosis for cancer,” he told me.
Source: Ivermectin and Fenbendazole May Just Quell Cancer - Mary Beth Pfeiffer
Case 10 (2025): 65-yr-old male with Early Lymphoma
A retired software programmer, Ridgway took long-established, off-patent drugs that are surely not on a typical oncologist’s radar: ivermectin, fenbendazole (a veterinary drug), and colchicine. They cost $400 for six months of treatment. Standard pharmaceuticals for early lymphoma, by contrast, cost an average $12,396 a year in the United States.
Ridgway, who is sixty-five years old, represents a small share of cancer patients who choose alternative care in part because they mistrust profit-driven oncology and dislike the chemo drawbacks. The drugs they take—under the supervision of a physician and sometimes with traditional therapies—are supported by considerable laboratory and animal studies and some human research.
For cases in which the outcomes are known, he prescribed his ivermectin-fenbendazole cocktail to sixteen patients, who almost all had been given one to four weeks to live. Thirteen survived from six to ten months before dying, he said. One near-death pancreatic patient, who had exhausted the gamut of chemotherapy, lasted more than a year.
“It’s difficult to reverse the (chemotherapy) damage,” DeMello said, who has six other cases in various treatment stages.
In two of his first sixteen cases, however, patients bypassed traditional care and went first to DeMello. Rohini Hughes, a fity-three-year-old advanced colon cancer patient, is alive though suffering, twenty months after her remaining time was measured in days. Mike Ridgway, whose cancer was caught early, was given a clean bill of health nearly a year after the disease emerged.
“I cannot overstate how blessed my wife and I feel,” Ridgway said.
Ridgway became friends with DeMello through Facebook, where they shared like-minded views of the flaws of official pandemic policies.
Ridgway’s first inkling that he was facing a serious health problem was in February 2024 after suffering abdominal pain and enlarged lymph nodes. “This PET scan will find cancer anywhere in your body,” the technician told a startled Ridgway.
Indeed, the scan showed “two nodes in the left upper abdominal mesentery that are markedly hypermetabolic, and lymphoma is a primary consideration.”
An oncologist ordered a biopsy, telling Ridgway unequivocally, “The tissue is the issue.”
He turned to DeMello, who “was very, very emphatic against it,” Ridgway said.
“I am convinced that there is no useful role of biopsy (and risk of spreading cancer) especially when a non-invasive test like PET scan can confirm the presence of malignancy,” DeMello explained. “Two huge lymphomas” on Ridgway’s scan were diagnostic for him.
“Unless he had a major infection, with symptoms of fever, high WBC counts, high neutrophil counts,” he said, “the only diagnosis for such huge tumors in the abdomen is malignancy’.”
After that, Ridgway opted to follow the advice of a doctor he respected half a world away.
“It’s nothing short of a miracle that the two of us were in communication when I received my diagnosis for cancer,” he told me.
Case 9: 49 year old Georgia man with Stage 4 Diffuse Large B-Cell Lymphoma in mesentery
Dr William Makis shared on X/Twitter in May 2025:
IVERMECTIN and FENBENDAZOLE Testimonial - 49 year old Georgia man with Stage 4 Diffuse Large B-Cell Lymphoma in mesentery has almost complete response after 3 months and NO CHEMO!
A lymphoma case. Almost complete response.
The most shocking part: NO CHEMO!
STORY:
49 year old Georgia man presented to ER in Oct.2024 with a large abdominal mass, pain and ascites.
He was diagnosed with Stage 4 Diffuse Large B-Cell Lymphoma
He had very bad side effects with 1st cycle of R-CHOP chemo and did not want to repeat any more chemo treatments.
I don't know how they found me, but in early January 2025 we started:
Ivermectin 1mg/kg/day
Fenbendazole 1332mg/day
RESULTS after 3 months:
CT showed:
"Significant treatment response. Mass-like conglomerate in the left abdomen on previous exam demonstrating significant improvement. Minimal residual mesenteric nodularity measuring 3x2cm"
My Take….
Ivermectin and Fenbendazole are often dismissed as not having had any effect on the cancer when the patient also takes chemo. “Chemo did all the work”.
But when there is no chemo, and the cancer shrinks or disappears, the critics are silent.
There was no chemo in this case and the patient is almost cancer free after 3 months of Ivermectin and Fenbendazole only.
Horrible side effects with chemo.
No side effects with Ivermectin and Fenbendazole.
We're going for "Cancer Free" on the next scan.
I have had several Lymphoma success stories like this already.
In this case, the patient was more than willing to do chemo but became so sick with the 1st cycle (losing 20+ pounds), that he couldn't do another cycle.
Dr William Makis shared on X/Twitter in May 2025:
IVERMECTIN and FENBENDAZOLE Testimonial - 60 year old Oregon woman with Mantle Cell Lymphoma has up to 96% tumor shrinkage.
STORY:
60 year old Oregon Woman was diagnosed with Mantle Cell Lymphoma and bowel involvement.
As of December 2024 she was progressing on imaging scans.
We started in December 2024:
- Ivermectin 1mg/kg/day
- Fenbendazole 888mg/day going to 1332mg/day
Case 7: 83 year old Florida man was diagnosed with extensive Stage 3 Follicular Lymphoma (a slow-growing type of non-Hodgkin lymphoma)
Dr William Makis shared on X/Twitter in April 2025:
IVERMECTIN and FENBENDAZOLE Testimonial - 83 year old FLORIDA Man with Stage 3 Follicular Lymphoma has a dramatic response (almost 100% resolution), Oncologist refuses to believe it!
This is an incredible story for several reasons, but you'll have to read to the end, to find out
STORY:
83 year old Florida man was diagnosed with extensive Stage 3 Follicular Lymphoma
Oncologist put him on “watch and wait”
Patient came to me in early September 2024.
We started the Makis Ivermectin Cancer Clinic Protocol in early October 2024:
- Ivermectin 1mg/kg/day
- Fenbendazole 444mg/day
- Melatonin 120mg/day
RESULTS after 6 months, on PET/CT (April 2025):
"Dramatic improvement in the lymphadenopathy previously seen in the axillary regions bilaterally. Previously the largest right axillary lymph node at approximately 3.4 x 1.9 cm, currently 1.0 x 0.7 cm. Previous maximum SUV of 9.5, currently 1.3"
"Dramatic improvement in the retroperitoneal adenopathy"
"IMPRESSION: Dramatic improvement of the lymphadenopathy from the neck all the way through the groin. No new or enlarging lymph nodes seen. Only mild activity seen within the right axillary lymph node. Other lymph nodes are not able to be discerned above background significantly improved from the exam September 2024."
My Take:
I have never seen a Radiology report use the word “Dramatic” three times in the same report. And I have seen 10,000s of PET/CT Reports. Radiologists don’t get emotional with their language.
No chemo. No radiation. Almost all the cancer is gone.
But that’s not the best part of the story.
Best part is the reaction of the Oncologist:
“We discussed findings on PET…which did show improvement in his lymphadenopathy”
“We had extensive discussion about PET imaging”
“Discussed waxing and waning nature of lymphadenopathy”
TRANSLATION:
Waxing and waning = “Cancer comes and goes.”
In other words, the results are random. Yes, 99% of the cancer is gone but it was all coincidence.
He then refused to do a follow-up PET scan in 6 months! Heaven forbid the excellent results would confuse him even more!
CONCLUSION: This is an incredible story because:
1. No chemo, no radiation, only "watch and wait" from Oncologist
2. 6 months of low dose Ivermectin & Fenbendazole
3. 99% of cancer gone (one mildly active little lymph node remained)
4. Oncologist says cancer comes and goes and attributes the results to coincidence. Chance.
I can assure you that when you have "extensive adenopathy from neck through groin" that is Stage 3 Lymphoma (with SUVmax up to 12.0 on PET/CT), it doesn't just disappear if you close your eyes and wait.
This Florida Oncologist was so uncomfortable with the excellent results, he won't do a follow-up PET/CT scan. He'd rather close his eyes and pretend. Stay in the dark - it's the world he knows.
But guess what, repurposed drugs like Ivermectin and Fenbendazole are revolutionizing Cancer Care and more and more Oncologists are going to get "uncomfortable" with results they don't comprehend...
Case 6: 94 year old male with Large T-Cell Lymphoma
February 2025 case study from Dr William Makis (X/Twitter):
"My father is 94 years old and was diagnosed with large T cell lymphoma. He had a golf ball sized tumor on the top of his foot at the bend of his foot. All the doctors he saw said it wouldn't go away without radiation."
"At his age he chose not to do that. I talked him into trying Ivermectin. I started him on the 1mg/per kilogram as you suggested but my siblings fought me and said that was too much for him to take."
"He has been taking 12mg for the last five months and his tumor is now smaller than a pea and it hasn't been breaking open and bleeding like it had been."
"We are thrilled with the progress even the low dose of ivermectin has achieved." "Thanks for everything you are doing to help people all around the world"
I love my patients!!!
No chemo. No immunotherapy. No radiation.
Just. Ivermectin. 12mg.
Case 5: Young European Female with Large B-cell Lymphoma
November 2024 case study from Dr William Makis (X/Twitter):
IVERMECTIN and MEBENDAZOLE Testimonial - Young European woman with Large B-Cell Lymphoma cleared of cancer in 2 months!
A young woman with Large B-Cell Lymphoma started a regimen of Ivermectin and Mebendazole in late May 2024.
- Ivermectin 1mg/kg/day
- Mebendazole 200mg/day
- followed by R-CHOP x 2 cycles
Comparison between PET scans done in September and again in late November 2024
RESULT: Complete resolution of Large B-Cell Lymphoma on PET scans 2 months apart!
European Oncologist’s advice was to NOT take Ivermectin or Mebendazole during chemo (they're no better than the mRNA poisoned, cognitively impaired Oncologists here).
My advice was: “Please continue Ivermectin and Mebendazole during chemo”.
Case 4: Female with Hodgkin's Lymphoma (December 2024)
Case testimonial from PerilousPeg (X/Twitter):
"Dr Makis, my daughter just beat Hodgkin’s lymphoma with these drugs, supplements and a few other lifestyle changes. No chemo. No radiation. I have been telling people who are commenting on her video on TikTok with questions qbout ivermectin and fenbendazole to follow you."
Case 2: April, 2021
In 2020 my cancer returned, low grade lymphoma in the neck and chest. I refused to go on another course of chemotherapy and followed the Fenbendazole protocol instead. I decided not to inform the doctors on the protocol I will be using as they would argue that it is a crazy belief with no proof of success.
It is almost a year later today that I received my second biopsy and PET scan results coming back completely clear from any disease, meaning there were no signs of lymphoma found from the neck lymph node that was removed.
Case 1: December, 2021
My twin sister was diagnosed with stage 2 non-Hodgkin’s B-cell double hit lymphoma a few years ago, which is known to be a very aggressive cancer out there. She won the battle, but not so long ago found out that the lymphoma has returned.
As a family we had to weigh the options and see what the next best approach is to this fight against cancer and so her journey started on Fenben. Here is a list of the protocol and other supplements she used and still use today:
Case 3: 70s year old male with Diffuse Large B-Cell Lymphoma (December 2024)
IVERMECTIN and FENBENDAZOLE Testimonial - 70s year old patient with Diffuse Large B-Cell Lymphoma - dramatic impact in first two weeks!!
70s year old USA patient recently diagnosed with LYMPHOMA.
We started a high dose Ivermectin and Fenbendazole Protocol
"We visited my husband's oncologist today and my Husband's blood results were the best we've seen them since the beginning of all this."
"He has large B cell lymphoma"
In 2020 my cancer returned, low grade lymphoma in the neck and chest. I refused to go on another course of chemotherapy and followed the Fenbendazole protocol instead. I decided not to inform the doctors on the protocol I will be using as they would argue that it is a crazy belief with no proof of success.
It is almost a year later today that I received my second biopsy and PET scan results coming back completely clear from any disease, meaning there were no signs of lymphoma found from the neck lymph node that was removed.
Case 1: December, 2021
My twin sister was diagnosed with stage 2 non-Hodgkin’s B-cell double hit lymphoma a few years ago, which is known to be a very aggressive cancer out there. She won the battle, but not so long ago found out that the lymphoma has returned.
As a family we had to weigh the options and see what the next best approach is to this fight against cancer and so her journey started on Fenben. Here is a list of the protocol and other supplements she used and still use today:
- Fenbendazole (222mg for the first few months and the increased the doses to 444mg/double)
- CBD
- Curcumin
- Vitamin E
- Additional supplements (recommended by doctors in Mexico)
Leukemia (Acute Myelogenous Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL) (9 Cases)
Case 9: 56 year old Illinois man with Chronic Myeloid Leukemia (CML)
Dr William Makis posted on X.com in January 2026:
IVERMECTIN and FENBENDAZOLE Testimonial - 56 year old Illinois man with Chronic Myeloid Leukemia (CML) shares his success story!
IVERMECTIN and FENBENDAZOLE Testimonial - 56 year old Illinois man with Chronic Myeloid Leukemia (CML) shares his success story!
Sometimes Cancer patients send me their success stories full of enthusiasm and optimism
STORY:
56 year old Illinois man with Chronic Myeloid Leukemia (CML)
Started Ivermectin and Fenbendazole in July
and saw his WBC count drop 78.6 to 7.99 within 2 months
October 2025: "The very first thing the doctor said was: "someone told me you had leukemia but I can't find it"
"Dr. seems very happy and a little surprised at how well he is doing!"
Jan.2026: "I reached major molecular response below 0.1%...which is considered remission! This is usually achieved after 18 months...WBC 4.27"
Dr William Makis updated on X/Twitter in January 2026:
IVERMECTIN and MEBENDAZOLE Testimonial - 56 year old North Carolina man with CLL Leukemia reports after 8 months - normalization of blood work, Oncologist changes follow-up from 3 to 6 months.
IVERMECTIN and MEBENDAZOLE Testimonial - 56 year old North Carolina man with CLL Leukemia reports after 8 months - normalization of blood work, Oncologist changes follow-up from 3 to 6 months.
Leukemia success stories are amazing because mainstream Oncology claims NOTHING helps outside chemo.
STORY: 56 year old North Carolina man with CLL Leukemia
In May 2025 he started:
- Ivermectin 1mg/kg/day
- Mebendazole 1000mg/day
- CBD Oil 100mg/day
Case 8: 56 year old North Carolina man with Chronic Lymphocytic Leukemia (CLL) (Part 1)
Dr William Makis posted (X/Twitter) in October 2025:
IVERMECTIN and FENBENDAZOLE Testimonial - 56 year old North Carolina man with Stage 0 Chronic Lymphocytic Leukemia (CLL) normalizes blood counts after 4 months.
IVERMECTIN and FENBENDAZOLE Testimonial - 56 year old North Carolina man with Stage 0 Chronic Lymphocytic Leukemia (CLL) normalizes blood counts after 4 months.
I'm always happy to see Leukemia success stories, because Leukemia is not easy!
STORY: 56 year old North Carolina man with Chronic Lymphocytic Leukemia (CLL) Stage 0
He had NO COVID-19 Vaccines
He had NO chemo
He had NO conventional Oncology treatment
On May 16, 2025 he started:
- Ivermectin 1mg/kg/day
- Fenbendazole 1000mg/day
2 Case testimonials from Dr William Makis (X/Twitter) in January 2025:
IVERMECTIN and FENBENDAZOLE Testimonial - Two blood Cancer Cases: Acute Myelogenous Leukemia (AML) patient becomes "cancer free" and Chronic Lymphocytic Leukemia (CLL) patient improves 1st time in 2 years!
Case 1:
AML Patient diagnosed in October 2024
Immediately started 72mg Ivermectin and 1000mg Fenbendazole 3 days on 4 days off
Also did 2 rounds of chemo in November and December, and in December added oral chemo pill Venclexta
Results after 2 months of Ivermectin & Fenbendazole:
"His bone marrow biopsy from December 24th came back clear! His blood work is looking good."
"We are so thankful for men like you that are willing to do the right thing in the face of great persecution"
======
Case 2:
63M CLL patient with a high WBC count in Sep.2022, on “watch and see”
I didn’t go aggressive here, started: 70mg Ivermectin and 500mg Mebendazole:
Results:
WBC 16.1 (Oct.2) → 15.6 (Dec.6) —> 14.1 (Jan.15)
Lymphocytes 13.0 (Oct.2) —> 12.5 (Dec.6) —> 11.3 (Jan.15)
On Dec.11 I made a few minor adjustments:
increased from 500mg to 1000mg/day Mebendazole and added 1000mg/day Lactoferrin.
After 2 years of being abnormal, the WBC and Lymphocytes are trending towards normal range (almost there)!
"It is definitely trending down since beginning the protocol"
Right now, there is only one peer reviewed publication that has documented the use of Ivermectin in Human Cancer Patients.
Can you guess what the Cancer is?
Leukemia. And it's behind a paywall.
2020 de Castro: "Continuous high-dose Ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection"
Case 5: Adult T-cell Leukemia/Lymphoma (ATL)
A patient with ATL and HTLV-1 infection was successfully stabilized and discharged after a combination of ivermectin and chemotherapy. The authors note that ivermectin may have contributed to disease control, but no firm conclusions can be drawn. (Lai Yuwen et al 2025)
A patient with ATL and HTLV-1 infection was successfully stabilized and discharged after a combination of ivermectin and chemotherapy. The authors note that ivermectin may have contributed to disease control, but no firm conclusions can be drawn. (Lai Yuwen et al 2025)
Several patients receiving hematopoietic stem cell transplants or undergoing treatment for leukemia were treated with ivermectin for Demodex or other parasitic infections. In these cases, skin symptoms resolved rapidly, and patients remained stable over the short-to-intermediate term, though direct anticancer effects were not confirmed. (Lai Yuwen et al 2025)
A female patient diagnosed with crusted scabies showed improvement after treatment with 9 mg ivermectin (days 1, 2, 8, 9, and 15) and systemic 5% permethrin cream for seven days. Two weeks later, all the skin lesions in the patient were repaired. (Lai Yuwen et al 2025)
In the case series by De Castro et al. (2020), a daily dose of 1 mg/kg was administered for six months. This regimen was found to be well tolerated, with no major side effects reported throughout the treatment period. Notably, the authors also observed clinical benefits associated with this dosing protocol.
A 6-year-old male with ALL remained well and in long-term remission after ivermectin treatment for Demodex folliculorum infestation. 200 μg/kg ivermectin and 5% permethrin cream were administered, and the treatment was repeated after seven days; the rash did not recur. No relapse or progression noted at follow-up. (Int J Dermatol 2003)
Case 1: 6-year-old male with Acute Lymphoblastic Leukemia (ALL) and Demodex folliculorum infestation
Discussion
Biological Plausibility: A Foundation Worth Examining
Mebendazole
Mebendazole disrupts microtubules, similar in principle to vincristine — a core drug in many lymphoma regimens. Preclinical studies have also suggested:
Induction of apoptosis in leukemia cell lines
Anti-angiogenic effects
Hedgehog pathway inhibition
Potential synergy with chemotherapy
Importantly, hematologic malignancies are particularly sensitive to microtubule dynamics, making mechanistic overlap notable.
Ivermectin
Ivermectin’s proposed anticancer mechanisms include:
WNT/β-catenin pathway inhibition
PAK1 modulation
Mitochondrial dysfunction induction
Immune signaling modulation
Some leukemia models demonstrate selective cytotoxicity at higher concentrations.
Translational Tension
A recurring issue in repurposing research is pharmacokinetics. In vitro concentrations do not always translate to achievable human plasma levels. However, tissue accumulation, tumor microenvironment effects, and immune modulation are variables not fully captured in cell culture models.
Thus, the mechanistic plausibility is neither trivial nor definitive.
What the 29 Cases Suggest — Without Overstating
Across the reported lymphoma and leukemia cases, several patterns emerge:
Many patients used ivermectin and/or mebendazole alongside standard chemotherapy.
Some reported rapid tumor regression within months.
PET-confirmed remission was described in select lymphoma cases.
Minimal toxicity was reported in anecdotal accounts.
In certain early-stage or indolent leukemia cases, hematologic markers reportedly normalized.
These are observational patterns — not controlled outcomes. Yet they raise several research-relevant questions:
Could these drugs act as chemosensitizers?
Might there be subtype-specific responsiveness?
Are certain metabolic or molecular profiles more susceptible?
Is immune modulation contributing indirectly?
The Evidence Gap: Where We Stand Clinically
Currently, the published clinical literature shows:
No phase III trials in lymphoma or leukemia
No randomized controlled trials establishing benefit
Limited early-phase exploration in oncology overall
No survival endpoint data in hematologic malignancies
In evidence hierarchy terms, this places the field at the hypothesis-generating stage.
However, absence of high-level evidence does not equal evidence of absence. It indicates an untested space.
Interpreting the Cases Through Multiple Lenses
Possibility 1: Attribution BiasStandard lymphoma therapies like R-CHOP achieve high remission rates. Improvements observed during combination use may simply reflect expected treatment response.
Possibility 2: Additive or Synergistic EffectPreclinical synergy data raise the possibility that these agents could enhance conventional treatment response without being independently curative.
Possibility 3: Indolent Disease VariabilitySome leukemias (e.g., early CLL) fluctuate naturally. Marker normalization may reflect disease biology rather than intervention.
Possibility 4: Early Translational SignalHistorically, many oncology breakthroughs began as small, observational signals before structured trials validated them.
The present data cannot distinguish among these possibilities.
Safety Profile: A Key Variable
One reason these drugs attract attention is their established safety record in antiparasitic use. That said:
Oncology dosing duration differs from short antiparasitic courses.
Drug–drug interactions with chemotherapy are under-studied.
Long-term hepatic or hematologic effects require structured monitoring.
The safety advantage hypothesis remains plausible but unproven in cancer contexts.
What Makes Hematologic Malignancies an Interesting Target?
Compared to solid tumors:
Blood cancers often rely on microtubule-targeting drugs.
Circulating malignant cells may be more accessible to systemic agents.
Immune modulation plays a central role in lymphoma biology.
Metabolic vulnerabilities may differ from solid tumors.
These features make mechanistic exploration in lymphoma and leukemia particularly compelling.
A Research Roadmap
If these case patterns are to be meaningfully evaluated, the next logical steps would include:
Pharmacokinetic studies confirming tumor-relevant concentrations.
In vitro synergy testing with R-CHOP components.
Phase I dose-finding safety trials in relapsed lymphoma.
Biomarker stratification (e.g., MYC, WNT activity, metabolic signatures).
Phase II objective response rate trials.
Randomized adjunct studies measuring progression-free survival.
Without this progression, the conversation remains anecdotal.
Where This Leaves Clinicians and Patients
At present:
Ivermectin and mebendazole remain investigational in lymphoma and leukemia.
They are not guideline-recommended therapies.
Standard-of-care treatments remain the evidence-backed foundation.
Clinical trial enrollment remains the safest pathway for exploration.
For researchers, however, these reports represent something different:
A cluster of biological plausibility intersecting with real-world experimentation.
Conclusion
The 29 reported cases neither confirm nor refute the anticancer potential of ivermectin and mebendazole in hematologic malignancies.
They represent a signal — faint, uncontrolled, and methodologically limited — but not biologically implausible.
The appropriate scientific response is not adoption or rejection.
It is investigation.
Whether this signal fades under scrutiny or strengthens through structured trials will determine its place in oncology. Until then, it remains an open question — and an area worthy of careful, disciplined research.
.png)
.png)
Comments
Post a Comment